eCommons@AKU
Section of Haematology/Oncology

Department of Medicine

January 2011

Incidence and impact of baseline electrolyte
abnormalities in patients admitted with
chemotherapy induced febrile neutropenia.
Asim Jamal Shaikh
Aga Khan University

Samira Ahmed Bawany
Aga Khan University

Nehal Masood
Aga Khan University

Ausaf Ahmed Khan
Aga Khan University

Ahmed Nadeem Abbasi
Aga Khan University
See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_med_haematol_oncol
Part of the Hematology Commons, and the Oncology Commons
Recommended Citation
Shaikh, A., Bawany, S., Masood, N., Khan, A., Abbasi, A., Niamutullah, S., Zaidi, A., Adil, S., Kumar, S. (2011). Incidence and impact of
baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia.. Journal of Cancer, 2, 62-6.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/4

Authors

Asim Jamal Shaikh, Samira Ahmed Bawany, Nehal Masood, Ausaf Ahmed Khan, Ahmed Nadeem Abbasi,
Syed Najeeb Niamutullah, Adnan Zaidi, Salman Adil, and Shiyam Kumar

This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/4

Journal of Cancer 2011, 2

62

Journal of Cancer
Research Paper

2011; 2:62-66
© Ivyspring International Publisher. All rights reserved

Incidence and Impact of Baseline Electrolyte Abnormalities in Patients
Admitted with Chemotherapy Induced Febrile Neutropenia
Asim Jamal Shaikh1, Samira Ahmed Bawany1, Nehal Masood1, Ausaf Ahmed Khan1, Ahmed Nadeem
Abbasi2, Syed Najeeb Niamutullah1, Adnan Zaidi1, Salman Adil1 and Shiyam Kumar1
1. Department of medicine, Section of Hematology and Oncology, The Aga Khan University Hospital, Karachi, Pakistan.
2. Department of Radiation Oncology, The Aga Khan University Hospital.
 Corresponding author: Dr. Asim Jamal Shaikh, Senior Specialist Registrar, Oncology Unit Dubai Hospital, Dubai, UAE.
Asim.jshaikh@hotmail.com
Received: 2010.10.06; Accepted: 2011.01.06; Published: 2011.01.25

Abstract
BACKGROUND: Febrile neutropenia (FN) and myelosupression remain a challenging oncologic medical emergency and dose limiting toxicity associated with chemotherapy for
cancers. Various factors are known to affect the outcomes for patients diagnosed with FN.
Electrolyte abnormalities have commonly been observed, but the real incidence and their
impact has been only scarcely studied in literature.
METHODS: This was a prospective, observational study. A total of two hundred and fifteen
(215) patients admitted between January 2007 and August 2008 were included. Analysis of
data was made using SPSS version16.0.Toxicity profile was graded according to CTC version
3.0.
RESULTS: Almost equal number of FN was observed in both solid tumors and hematological
cancers with almost equal gender distribution. Of all 83.5% patients demonstrated some
electrolyte abnormalities. All grades combined, hypokalemia was seen in 48% of patients, with
51.4% having grade I, 33.3% grade III and 15.2% G IV (life threatening) hypokalemia. Hyponatremia of all grades was seen in 67.9% patients, of them 60.3% had Grade I, 33.3% grade III
and 0.7% patients had grade IV hyponatremia. Hypomagnesaemia (70 patients assessed) was
seen in 54.3% patient, 94.7% having grade I decline. Average length of stay for patients who
received IV electrolyte replacement was 6.3 days compared to 4.9 days in those who did not.
Out of 90 patients who required special care unit 75 had electrolyte abnormalities, of 15
patients who expired 13 had electrolyte abnormalities
CONCLUSION: This analysis, which is first of its kind, suggests that decline in electrolyte
levels is frequently observed in patients presenting with FN. These abnormalities can have
independent negative impact on the outcome for such patients. Special attention should be
paid to electrolyte imbalance right from the outset.
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Introduction
Febrile neutropenia (FN) and myelosupression
remain a challenging oncologic medical emergency,
and dose limiting toxicity associated with chemotherapy for cancers [1]. Although availability and choice

of antibiotics has progressed over the years, FN and
its associated complications remain a major source of
morbidity, inpatient stay, cost and mortality [2]. The
average cost for management of FN in USA is quoted
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to be as high as US $15,231 for inpatient therapy and
US $7,772; for outpatient management [3]. Mortality
rates from febrile neutropenia are reported to range
from as low as 5% in an average risk cohort to as high
as 82% in high risk patients [2]. Analytical models to
predict outcomes and length of in hospital stay (LOS)
in FN patients based on presentation, co morbid conditions, biochemical parameters, type of malignancy
and disease burden have been proposed and are used
in clinical practice [4-6]. Algorithmic approaches to
treat FN have been developed based on clinical parameters. Standard approach to treatment included
obtaining specimens to identify focus of infection and
begin empiric antimicrobial therapy based on local
microbiological data, as delay in initiating treatment
is associated with worse outcome [7]. Although used
frequently, role of colony stimulating factors, in primary and or secondary settings is controversial [2, 8].
Modalities have been identified to risk stratify patients and treat those having logistic reasons by outpatient pre-emptive approach with good outcomes
[9]. The degree of neutropenia and severity of infection depends upon dose intensity of the chemotherapy and is therefore different for various chemotherapies [10]. The incidence of FN depends on the type of
chemotherapy with rates close to 98% for patients
undergoing high dose chemotherapy with hematopoietic stem cell rescue during the pre engraftment
neutropenic phase and about 10-20% in patients going
standard treatment for cancer such as Non Hodgkin’s
lymphoma (NHL) [10].
Electrolyte imbalances per se have not been studied with relation to affect on outcomes in FN so far.
The incidence and importance of abnormalities in
electrolytes like Na, K, Mg and Ca is unknown. Based
on our observation that patients reporting as inpatients for management of FN also frequently required
intravenous electrolyte replacements, we conducted a
prospective study of all patients coming to in patient
care for the assessment of their electrolyte abnormalities and its possible association with, clinical presentation, length of stay, response to therapy, association
with chemotherapy regimen, type of malignancy and
the final outcome.

Material and Methods
This was a prospective study conducted from
January 2007 to August 2008. All patients who were
admitted with the diagnosis of chemotherapy induced
febrile neutropenia were included. Febrile neutropenia was defined as single temperature of >38.3ºC
(101.3ºF), or a sustained temperature >38ºC (100.4ºF)
for more than one hour, in a patient with absolute
neutrophil count (ANC) of < 500. Electrolyte abnor-
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malities observed on admission were recorded and a
Performa was filled in to document all the relevant
data. National cancer institute toxicity criteria (NCCI
toxicity Scale) version 3.0 was used to grade the electrolyte abnormalities observed. Data was entered into
Microsoft Excel Sheet© and final analysis was made
by Statistical Package for Social Sciences (SPSS) version 16.1. Chi Square and Fischer’s Exact Tests were
utilized for analysis of statistical significance of results.

Results
A total of 215 patients who were admitted at our
hospital with chemotherapy induced febrile neutropenia were included. Almost equal number of males
and females were found to be affected with 107 patients being male and 108 female. The mean age was
51.53 years; the average age of males was 49.93 years
and average age in females was 52.95 years. Most of
the patients presented at the Emergency Department
(70%) while the rest presented to the clinic or were
referred by outside physicians. Patients had underlying hematological malignancy in 48.8 % of cases while
51.2% had solid organ tumors. The most common
underlying malignancy was breast cancer (25.6%),
followed by non-Hodgkin’s Lymphoma (22.8%) and
Acute Myelogenous Leukemia (12.6%). Other notable
but less common malignancies seen in our patients
were ovarian cancer (7.4%), Acute Lymphocytic Leukemia (5.6%) and Sarcoma (3.3%). Most of the patients
(31.6%) presented with febrile neutropenia after they
received their first cycle of chemotherapy, with 14%
being affected twice, 20% developing it for the third
time, 13% for the fourth time, and 7% for the fifth
time.
Electrolyte abnormality of all grades combined
was seen in 83% of patients. Hypokalemia, of any
grade, was seen in 48% of patients. Among those
51.4% had grade I, 33.3% had grade III and 15.2% had
grade IV hypokalemia. Hyponatremia of all grades
was seen in 67.9% patients, 60.3% had Grade I, 33.3%
grade III and 0.7% patients had grade IV hyponatremia. Hypomagnesaemia was seen in 54.3% patient,
94.7% having grade I decline. Of all 65% of our patients received intravenous (IV) electrolyte replacement. Gender distribution across the patients demonstrating electrolyte imbalance was found to be similar
with 85% males and 83% of the females affected. Average length of stay in patients who received IV electrolyte replacement was 6.3 days compared to 4.9
days in those who did not (p < 0.016). In those patients
who were successfully discharged the average length
of stay was 5.4 days whereas it was 11.4 days in patients who died (p value < 0.0001). Intravenous sohttp://www.jcancer.org
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dium replacement was given to 66% of patients.
Among patients who had hypokalemia, 73% required
IV replacement while 58% of patients were also given
oral potassium replacement.
We observed that 42% patients were admitted to
rooms with isolation protocol. Rest of the patients
were admitted to the either general ward (19%), or
private rooms (38%). Special care unit transfer was
required in 90 patients (41.8%) during the course of
their stay, of these 75 patients (83.3%) were found to
have electrolytes abnormalities most commonly hypokalemia (87%). The mean age in patients who died
was 51.05 years; average age of males who expired
was 50.46 years and that of females who expired was
52.57 years. Co-existing vomiting, diarrhea or both
was seen in 12% of patients with electrolyte deficit. In
all 199 patients (92.5%) were successfully discharged
after management of FN, 15 patients (6.9%) died. One
patient left against medical advice. Electrolyte abnormalities were seen in 86.6% (n=13) of those who
died. Hyponatremia of grade III was seen in 56% of 9
patients who died, Grade II hypokalemia was seen in
4 patients who had hypokalemia alone or in combination with hyponatremia. Overall more deaths were
reported in patients admitted under isolation (8.9%)
than in patients admitted to the general ward (7.3%)
or private rooms (3.7%). Patients presenting to the
Emergency were more likely to die (8.7%) compared
to patients who were referred from elsewhere. We
found that there were more deaths in males, as rate of
mortality was 26.6% for females and 73.3% for males.
Among those who died males demonstrated more
electrolyte abnormalities compared to females (90%
vs. 75%).

Discussion
Chemotherapy induced FN is a serious oncologic
emergency with a potential to have a fatal out-come
[11, 12]. There are on average about 200 admissions in
a year, to our hospital with a diagnosis of chemotherapy induced febrile neutropenia. Clinical parameters
to predict outcomes in FN patients have been studied
and various risk stratification guidelines are proposed
[11][5]. In the present era of modern antibiotic therapy, where coverage against most infective organisms
is available, factors other than infection itself are becoming increasingly evident as predictors of outcome
in FN [13]. Electrolyte abnormalities per se have not
been as yet nominated as one of the factors for predicting a worse outcome, indirectly though, mucosal
breach associated with cytotoxic chemotherapy has
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been suspected to be a cause of worse out comes in
patients having cytopenia secondary to chemotherapy, compared to those who have neutropenia secondary to viral infections [14]. What exactly causes the
electrolyte abnormalities that are observed with FN
remains to be elucidated, but results from our study
suggest that it seems very unlikely that only vomiting
or diarrhea associated with chemotherapy are the
cause, as only 12% of our patients were found to have
the two co-exist. Similarly most of the patients also
had a preserved renal function when depicting electrolyte loss. Analyzed as a single variable, electrolyte
abnormalities requiring IV administration resulted in
a longer stay by approximately more than one and
half days (Figure 3). The fact that most of the patient
who died had some degree of electrolyte imbalance,
both hypokalemia and hyponatremia, carries weight
but is not statistically significant because of a smaller
sample size. The need of IV replacement of K+ made
shifting of patients to special care rooms with cardiac
monitor necessary, the special care transfer and longer
stay are a reason for increasing treatment cost [15]. We
did not find any difference with regards to gender or
type of malignancy (whether solid or hematological)
with reference to development of FN and/or electrolyte deficit, but we saw that more male patients who
died demonstrated electrolyte imbalance compared to
females. The overall mortality attributed to FN in our
series was comparable to that seen in international
literature. Whereas, we observed almost a similar
number of patients suffering from hematological and
solid tumors, most of the published literature shows a
trend towards more incidence for hematological cancers [11]. We, in contrast, to other studies did not find
the increasing age to be more associated with deaths,
we assume that the reason is because more elderly
patients are given prophylactic G-CSFs now, then
before, therefore the number would have been quite
less to affect the analysis.
The various factors associated with increasing
cost, morbidity and mortality continue to be studied,
with many being already validated. Our study points
out that Electrolyte abnormalities and specially those
requiring IV replacement, result in a longer length of
stay and cost of treatment. We observe that deficits of
Na + and / or K + are also frequently seen in patients
dying with FN. Whether routine recommendation of
measures that prevent electrolyte deficit such as oral
rehydration salts will result in better outcome in patients receiving chemotherapy, require larger prospective studies.
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